For what the Franco-Canadian panel on 29 May highlighted was not so much what distinguishes the two countries as what brings them together structurally: internationally recognised academic foundations – Inserm, CNRS, Institut Pasteur and CEA on the French side, and major universities on the Canadian side (Vancouver, Toronto, Montreal, etc.) which Ottawa is seeking to specialise –; recognised regulatory capacity; but also a shared difficulty in transforming this scientific excellence into industrial champions. This challenge of translational research – how to make the leap from discovery to industrialisation? – is precisely where this cooperation can create value.
On the agenda
• Overview of the French and Canadian biomanufacturing ecosystems • Industry and academic perspectives and insights • Competitiveness, sovereignty and health emergency preparedness challenges • Public-private partnerships, technology transfer and innovation • Opportunities for France–Canada collaboration in biomanufacturing
Speakers
Laurent Lafferrère (Chief Executive Officer, France BioLead) · Ritu Banerjee (Acting Head, Health Emergency Readiness Canada) · Anne Jouvenceau (Coordinator of the Acceleration Strategy for Biotherapies and Biomanufacturing in Innovative Therapies, Health Innovation Agency) · Mark Lievonen (Member of HERC’s Council of Expert Advisors, Principal, JML Advisory Services and former President, Sanofi Pasteur) · Philippe Charreau (VP Manufacturing & Supply France, Sanofi) · Trina Racine (Director of Vaccine Development, Vaccine and Infectious Disease Organization) · Nadège Nief (Deputy Director, Microtechnologies for Biology and Health Division, CEA Leti) · Christophe Junot (Director, Joliot Institute, CEA)
Moderator
Fabien Nizon, Journalist, Pharmaceutiques
